Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Tokuyama ( (JP:4043) ).
Tokuyama Corporation has completed the acquisition of a newly established company that will take over JSR Corporation’s in vitro diagnostic pharmaceutical business. This strategic move involves the transfer of the business to a new subsidiary, Tokuyama Life Science Corporation, which will enhance Tokuyama’s capabilities in the diagnostics sector. The acquisition is expected to bolster Tokuyama’s market presence and operational capacity, although the financial impact is still being assessed.
The most recent analyst rating on (JP:4043) stock is a Buy with a Yen3800.00 price target. To see the full list of analyst forecasts on Tokuyama stock, see the JP:4043 Stock Forecast page.
More about Tokuyama
Tokuyama Corporation operates in the chemical industry, focusing on products such as in vitro diagnostics and pharmaceutical materials. The company is involved in various sectors, including healthcare, and aims to strengthen its market position through strategic acquisitions.
Average Trading Volume: 489,332
Technical Sentiment Signal: Buy
Current Market Cap: Yen268.7B
Learn more about 4043 stock on TipRanks’ Stock Analysis page.